Gilead (GILD) Slips Despite Strong Q3 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. NVDA
2. SPY
3. META
4. VRTX
5. LGND
6. ONON
7. PSKY
8. TDY
9. ANF
10. LH

Go back to Gilead (GILD) Slips Despite Strong Q3 Results

Gilead Sciences (GILD) raises Revenue Guidance Following 3Q Beat; Maxim Group Reiterates Buy

October 28, 2015 1:47 PM EDT

Maxim Group reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD), and raised the price target to $137.00 (from $129.00), following the company's 3Q earnings results. Gilead delivered a very strong quarter well ahead of street estimates. Gilead raised guidance for full year... More

Gilead Sciences (GILD) PT Raised at Cowen as HCV Sales Drive Beat

October 28, 2015 8:53 AM EDT

Cowen analyst Phil Nadeau reiterated an Outperform rating and bumped his price target on Gilead Sciences (NASDAQ: GILD) to $130.00 (from $125.00) as HCV sales drove the top and bottom-line and guidance was ralsed.

Nadeau commented, "Gilead reported solid Q3 financials with HCV revenue... More

Gilead Sciences (GILD) Bullish Stance Reiterated at Oppenheimer Amid 'Beat and Raise' Qtr

October 28, 2015 6:25 AM EDT

Oppenheimer analyst Wendy Lam reiterated an Outperform rating and $124 price target on Gilead Sciences (NASDAQ: GILD) following 'beat and raise' Q3.

Lam commented, "GILD reported a healthy 3Q15 beat, with revenue and non-GAAP EPS of $8.30B and $3.22 topping Street consensus estimates of $7.81B and $2.87; GILD... More